MiRNA-based therapy for p53-deficient tumors: IAPP (Amylin) increases the expression of tumor suppressor MiRNA-34 and induces regression of p53-mutated human tumors via up regulation of its target gene, 16/May/2015, 23.49

T2DM drugs as Lifespan extenders: Acarbose, a widely used drug in the treatment of T2DM, inhibits senescence and extends life span by down regulating the expression of adenylate cyclase 5 (ADCY5), 16/May/2015, 19.00
May 16, 2015
Natural product-based accelerated healing therapy for Diabetic patients: Agaricus blazei Murill (AbM) enhances wound healing in diabetic patients via down regulation of its target gene, 16/May/2015, 23.04
May 16, 2015
Show all

A recent study from the Department of Molecular and Cellular Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA [2] Department of Translational Molecular Pathology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA [3] Graduate School of Biomedical Sciences, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA [4] Metastasis Research Center, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA shows that“IAPP-driven metabolic reprogramming induces regression of p53-deficient tumours in vivo.” This study was published in the 29 January  2015 issue of the Journal “Nature” (the no.1 journal in Science with an impact factor of 42) by Prof. Flores ER, Venkatanarayan A and others.

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  MiRNA-based therapy for p53-deficient tumors: IAPP (Amylin) increases the expression of tumor suppressor MiRNA-34 and induces regression of p53-mutated human tumors via up regulation of its target gene

Significance:  

Although IAPP has been shown to induce regression of p53-deficient tumours in vivo, the mechanistic basis of which remains unclear.  This study suggests, for the first time, that IAPP (Amylin), by increasing the expression of its target gene, it may increase the expression of tumor suppressor MiRNA-34. Thereby, it may induce regression of p53-mutated human tumors. Thus, pharmacological formulations encompassing IAPP or its analogues  can be used to inhibit the progression of p53-deficient human tumors.

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Web: http://genomediscovery.org

CitationBoominathan,  MiRNA-based therapy for p53-deficient tumors: IAPP (Amylin) increases the expression of tumor suppressor MiRNA-34 and induces regression of p53-mutated human tumors via up regulation of its target gene, 16/May/2015, 23.49, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

Undisclosed information: How IAPP (Amylin) increases the expression of MiRNA-34

* Research cooperation

Comments are closed.